Aravive Inc

Aravive — Investor Presentation (June 2023)

38 slides from Aravive's investor presentation, Jun 5, 2023

  1. Slide 1: Developing Transformative Targeted Cancer Therapeutics

    ¢°9 aravive Developing Transformative Targeted Cancer Therapeutics Corporate Presentation June 2023 NASDAQ: ARAV

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements ‘This presentation contains forward-looking statements that may discuss Aravive's plans, goals, intentions and expectations as to future trends, ‘events, results of operations, financial condition or other matters. Forward- looking statements generally inclide statements t

  3. Slide 3: Batiraxcept: Novel Differentiated Late-Stage Clinical Program for Solid Tumors

    Batiraxcept: Novel Differentiated Late-Stage Clinical Program for Solid Tumors (%) GAS6/AXL signaling drives metastasis and drug-resistance. ARAV is the only company targeting GAS6. Wealth of preclinical studies demonstrate ability to combine with common standards of care to allow access to a large

  4. Slide 4: Experienced Management and Board of Directors

    Experienced Management and Board of Directors ‘Senior Management = Ts Dobe s, -_ 2 Foy Howes CPA Ratan eer, MD. Cr ates, BA Board of Directors fredtaaman tam. AmaioGacsnPD. Pera D.PRO. bn Hobme, MD. —«Sgudkek Galle PRO, OABT chon oes ect Furiex “YSenmab PACIRA KINNATE PIPIP vcore ORKERVX Akebia GSK

  5. Slide 5: Aravive Pipeline - Late Stage with Phase Data in Mid-2023

    Aravive Pipeline - Late Stage with Phase 3 Data in Mid-2023 Opportunity for Expansion into Additional Indications and Drug Combinations Batiraxcept LL 1 Toprine data mid-2028 1D. Potential BLA submission 4 2023, Patoun Restart varan Concer Rainn ast * praca enti sg noe— a Ireiglefr curate itt ray (t

  6. Slide 6: GAS6/AXL Pathway and Batiraxcept

    ¢°9 aravive @ GAS6/AXL Pathway and Batiraxcept (x)

  7. Slide 7: GAS6/AXL Signaling Drives Resistance and Metastasis

    GAS6/AXL Signaling Drives Resistance and Metasta: GASB is a survival switch in tumor cells but not essential in normal tissues’, which lowers the potential for side effects + GAS6/AXL pathway mediates metastasis + GAS6 and AXL expressed by tumor and tumor-associated stromal cells to promote tumor pr

  8. Slide 8: GAS6 & AXL Expression Associated with Poor Survival in Many Cancers

    GAS6 & AXL Expression Associated with Poor Survival in Many Cancers AXL expressed in 270% of ovarian, pancreatic, breast, kidney, and uterine cancers" “Clinically, the expression of GAS6 and TAM receptors always predicts poor prognosis’ ” Tumor | AXL Tumor seg (2 Publications & Ds Hao et al 2017. AX

  9. Slide 9: Effective Oncology Treatment Requires Targeting Both Non-metastatic and Metastatic Tumor Cells

    Effective Oncology Treatment Requires Targeting Both Non- metastatic and Metastatic Tumor Cells Batiraxcept specifically targets metastatic tumor cells » Batiraxcept demonstrates single agent activity in preclinical models which have homogeneous, metastatic tumor cells + Human tumors display epithel

  10. Slide 10: Batiraxcept is a High Affinity Decoy That Mimics AXL Receptor

    Batiraxcept is a High Affinity Decoy That Mimics AXL Receptor Improves on shortcomings of other approaches for potent and selective inhibition of the AXLIGAS6 pathway ‘Baticaxcopt mimics AXL to bind and Very Ab psa UL x ae mane eet er ta seve en © negate » Eee Oca fons te pe Been * stare metre «Nato

  11. Slide 11: Batiraxcept: High Affinity AXL Decoy Protein

    Batiraxcept: High Affinity AXL Decoy Protein Inhibits the GAS6/AXL Pathway by Sequestering the GAS6 Ligand Modified AXL-Fe fusion protein engineered for stability and very high affinity for GAS6 + ~200-fold greater affinity for GASG than the native AXL receptor allows for effective inhibition + Prec

  12. Slide 12: Dosing Strategy Varies by Indication

    Dosing Strategy Varies by Indication Batiraxcept exposure correlates with anti-tumor activity + Knockout data and GLP program did not identify DLT *+ Traditional MTD or DLT approach for identification of RP2D not appropriate for batiraxcept due to its benign safety profile — Approach consistent with

  13. Slide 13: ~$3B in Global Revenue Potential in PROC, Renal and Pancreatic

    ~$3B in Global Revenue Potential in PROC, Renal and Pancreatic* PROC Represents the Most Near-term Opportunity $3B Peak Potential for all 3 Indications Estimated Treatable Patients PDAC + 37.5K (USA) + 46K (EU4/UK) PROC + 10.5K patients (USA) + 13.9K patients (UK/EU4) ecRCC + 9K (USA) + 9.5K (EU4/UK

  14. Slide 14: Batiraxcept: Platinum-Resistant Ovarian Cancer (PROC)

    ¢°9 aravive @ Batiraxcept: Platinum- Resistant Ovarian Cancer (PROC) (x)

  15. Slide 15: Summary of Phase 1a Healthy Volunteer and 1b PROC Studies

    Summary of Phase 1a Healthy Volunteer and 1b PROC Studies No observed dose-limiting toxicities up to 20 mg/kg Phase 1a single ascending dose and repeat dose study in healthy volunteers + 43 subjects participated; 42 dosed + Batiraxcept was well-tolerated across doses of 1-10 mg/kg Batiraxcept; no SA

  16. Slide 16: Batiraxcept + Paclitaxel Clinical Activity Associated with Exposure in P1b PROC

    Batiraxcept + Paclitaxel Clinical Activity Associated with Exposure in Pib PROC Modeling Identified RP2D of 15 mg/kg for PROC + Exposure-response relationship identified by unsupervised computer analysis, ei for Patient: 19 10 mglk cy ei = Statistically significant relationship between high trough m

  17. Slide 17: Time on Treatment and Depth of Response for Batiraxcept + Paclitaxel Patients

    Time on Treatment and Depth of Response for Batiraxcept + Paclitaxel Patients (10 and 15 mg/kg groups) 96% were on 3% Line of Therapy; Literature Demonstrates 85% of Patients on their 3° Line of Therapy have Progressive Disease by their First CT Scan‘ [PFS Month or Per-Protocol 10 mg/kg and 18 ma/hg

  18. Slide 18: Batiraxcept + Chemo - Better Response than Chemo Monotherapy

    Batiraxcept + Chemo - Better Response than Chemo Monotherapy Phase 1b Results Compared to Literature These Tumors Expected to be Dependent on the GAS6/AXL Pathway Chemotherapy Alone Batiraxcept + Chemotherapy’ Patients with = *~ <3mo Platinum 408 Freeinterval = = Ca) : — _ - — _| nat) neta) 3° and 4

  19. Slide 19: Batiraxcept Phase 3 Registrational Trial Design in PROC

    Batiraxcept Phase 3 Registrational Trial Design in PROC (ClinicalTrials.gov NCT04729608) + FDA Feedback: If positive, trial could support full approval in PROC; no further preclinical or clinical studies required for BLA at this time + Endpoint Assessment: PFS per RECIST V1.1; radiological imaging e

  20. Slide 20: Market Research Suggests Batiraxcept Would Fill an Unmet Need in PROC

    Market Research Suggests Batiraxcept Would Fill an Unmet Need and Be Adopted into the Current PROC Treatment Paradigm To see this level of safety with the “The all-comers data is helpful to improvedefficacy is impressive know, but the bev-naive data is | certainly would use this product.” quite tran

  21. Slide 21: Batiraxcept: Clear Cell Renal Cell Carcinoma (ccRCC)

    ¢°9 aravive @ Batiraxcept: Clear Cell Renal Cell Carcinoma (ccRCC) (x)

  22. Slide 22: Batiraxcept + Cabozantinib Phase 1b/2 Trial Design in ccRCC

    Batiraxcept + Cabozanti (NCT04300140) Phase ib atiraxcopt 2W (15 mghkg N=t6) (20 mplkg N=10) ‘Cabezantinib 60 mg OD Caza dang a8 inated on te pachge inert ib Phase 1b/2 Trial Design in ccRCC Pane Pane 1M0e = tratens! Meranave RCC Oxabase Consort (Rk). TK = tyrosine Knee intr (x)

  23. Slide 23: Batiraxcept + Cabozantinib Phase Trial

    Batiraxcept + Cabozantinib Phase 2 Trial (NCT04300140) Batiraxcept + Batiraxcept Cabo & Nivo Monotherapy N=11 (%) 0 (%) Median age in years (range) 66 (44-79) 59 (49-68) 67 (47 -83) ‘Sex (Male) 14 (56) 11.100) 8 (80) Race (Caucasian, Others) 21 (84), 4 (16) 9 (82), 2 (18) 8 (80), 2 (20) ECOG (0,1) 1

  24. Slide 24: P1b ccRCC: Safety Consistent with Established Profile for Cabozantinib

    P1b ccRCC: Safety Consistent with Established Profile for Cabozantinib All Pib Patients 45 mgikg P1b Patients | 20 mg/kg P1b Patients bed (N=26) (N=16) (N=10) Batiraxcept-Related Deaths ° ° 0 Grade 3 Adverse Events (AEs), 5 (19.2%) 3.(18.8%) 2 (20%) related to Batiraxcept Events: HTN(x2), Events: HT

  25. Slide 25: P2 ccRCC: Safety Consistent with Established Profile for Cabozantinib and Manageable

    P2 ccRCC: Safety Consistent with Established Profile for Cabozantinib and Manageable Diarrhea 25 Fatigue 26 Alkaline Phos Increased Infusion Related Reaction 20 LDH increased 28 AlTincreased 16 2 ‘ASTinereased 15, 2 Dysreusia 2 4 Nausea 2 Hypertension a6 PE Syndrome Decreased appetite Stomatitis Pat

  26. Slide 26: P2 ccRCC: First Line (1L) and Monotherapy

    P2 ccRCC: First Line (1L) and Monotherapy Results suggest that batiraxcept achieves greatest activity in combination therapies and support the approach in the planned registrational P3 trial + The addition of batiraxcept to cabo or cabo/nivo in 1L suggests no additive toxicity or effect compared to

  27. Slide 27: P1b/P2 ccRCC: Clinical Activity by Prior VEGF-TKI Status

    P1b/P2 ccRCC: Clinical Activity by Prior VEGF-TKI Status Designated Fast Track by FDA for patients who have progressed after 1 or 2 prior lines of systemic therapy that include both immuno-oncology (IO)-based and vascular endothelial growth factor tyrosine kinase inhibitor (VEGF-TKI)-based therapies

  28. Slide 28: Batiraxcept Phase 3 Registrational Trial Design in ccRCC

    Batiraxcept Phase 3 Registrational Trial Design in ccRCC + Designated Fast Track by FDA in Nov 2022 for patients who have progressed after 1 or 2 prior lines of systemic therapy thatincludeboth immuno-oncology (10)-based and vascular endothelial growth factor tyrosine kinase inhibitor (VEGF-Tk{)-bas

  29. Slide 29: Market Research Suggests Batiraxcept Would Fill an Unmet Need in ccRCC

    Market Research Suggests Batiraxcept Would Fill an Unmet Need and Be Adopted into the Current ccRCC Treatment Paradigm “ The upside efficacy would be practice-changing in 2L ... | would offer it to most of the biomarker positive population.” = KOL Improved Performance over Cabozantinib Improved perf

  30. Slide 30: Batiraxcept: Pancreatic Adenocarcinoma

    ¢°9 aravive o Batiraxcept: Pancreatic Adenocarcinoma » (s)

  31. Slide 31: Phase 1b Design in 1L Pancreatic Adenocarcinoma

    Phase 1b Design in 1L Pancreatic Adenocarcinoma (NCT04983407) Patients with advanced or metastatic pancreatic adenocarcinoma eligible to receive gemcitabine + nab- paclitaxel (Abraxane®) as first-line treatment Lead-InPhase Dose Escalation Batiraxcept Endpoints: demon cays G18) + Safety and tolerabi

  32. Slide 32: Safety Profile Consistent with Gemcitabine + nab Paclitaxel or Underlying Disease

    Safety Profile Consistent with Gemcitabine + nab Paclitaxel or Underlying Disease In P1b PDAC Study nab-Paciitaxel Batiraxcept-Related Deaths 0 = 6 (29%) Grade 3 Adverse Events (AEs), related to Batiraxcept events: Back Pain, Dizzinets ee ecuion (No Grade 4 or 5 AEs related to Batiraxcept)* Gaetan 2

  33. Slide 33: Batiraxcept in PDAC: Ongoing P1b Study - Efficacy

    Batiraxcept in PDAC: Ongoing P1b Study (NCT04983407) - Efficacy Patients with trough Levels>MEC remain longer on study and have higher response rates, suggesting higher batiraxcept doses may improve anti-tumor effect + Modeling studies identified MEC of wet batiraxcept in PDAC at 14.5 mg/L Be Consis

  34. Slide 34: Market Research Suggests Batiraxcept Would Fill an Unmet Need in PDAC

    Market Research Suggests Batiraxcept Would Fill an Unmet Need and Be Adopted into the Current PDAC Treatment Paradigm “ Ifthe biomarker high population were really 70%, I would serum test and give [the upside] to all my positive patients.” “ Efficacy in the base case is similar to FOLFIRINOX, | ike

  35. Slide 35: Anticipated Upcoming Milestones

    Anticipated Upcoming Milestones IF positive, submit Potential FDA Lief PS top-line results ia one ecRCC Initiation of P3 Updated P1b/2a data PDAC Updateddata from ritate p2a® P'1b dose escalation “Depend on mature ct fom Pb POAC sty

  36. Slide 36: Financial Summary

    Financial Summary $35.9 million Cash and Cash Equivalents As of 3/31/23 No Debt Cash Runway Expected to Fund Operations Into 4Q’ 2023

  37. Slide 37: Dedicated to Developing Innovative Treatments for Life-Threatening Diseases

    Dedicated to Developing Innovative Treatments for Life-Threatening Diseases to Increase Patient Sur Proprietary, differentiated first-in-class candidate inhibiting GAS6/AXL signaling pathway associated with tumor growth, metastasis, drug resistance, and poor survival rates | Batiraxcept has potentia

  38. Slide 38: Developing Transformative Targeted Cancer Therapeutics

    ¢:9 aravive Developing Transformative Targeted Cancer Therapeutics Corporate Presentation June 2023 NASDAQ: ARAV

Aravive — Investor Presentation (June 2023) on 6ix